Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04832009 · ClinicalTrials.gov registry record · Early Phase 1
Reversing Glucose and Lipid-mediated Vascular Dysfunction
A Early Phase 1 study of Hypertension and Blood Pressure, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT04832009 is a Early Phase 1 study of Hypertension and Blood Pressure that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 46 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04832009, a Early Phase 1 study of Hypertension and Blood Pressure, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of our study is to understand the extent to which the blood vessels are affected by glucose and fat (lipids) in lean healthy adults and if these changes in the blood vessels contribute to the development of high blood pressure.
Conditions Studied
Interventions
- DRUG Saline
- DRUG Ascorbic acid
- DRUG Dextrose 20 % in 500 ML Injection
- DRUG Intralipid
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2022-05-09 |
| Est. Completion | 2027-08-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04832009
The ClinicalTrials.gov registry entry for NCT04832009 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 4 interventions - of which Saline is the first listed.
NCT04832009 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT04832009 about?
NCT04832009 is a clinical study titled "Reversing Glucose and Lipid-mediated Vascular Dysfunction". The purpose of our study is to understand the extent to which the blood vessels are affected by glucose and fat (lipids) in lean healthy adults and if these changes in the blood vessels contribute to the development of high blood pressure.
What is the current status of trial NCT04832009?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 46 participants. The study started on 2022-05-09. Estimated completion is 2027-08-01.
What conditions does trial NCT04832009 study?
This clinical trial studies the following conditions: Hypertension, Blood Pressure.
What interventions are being tested in trial NCT04832009?
The interventions under investigation include: Saline (DRUG), Ascorbic acid (DRUG), Dextrose 20 % in 500 ML Injection (DRUG), Intralipid (DRUG).
Who is sponsoring clinical trial NCT04832009?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04832009 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1)
RECRUITING · Early Phase 1
-
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
RECRUITING · Early Phase 1
-
Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)
RECRUITING · Early Phase 1
-
Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)
RECRUITING · Early Phase 1
-
Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction
ACTIVE NOT RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.